Showing 41 - 60 results of 9,576 for search '(((( 50 ng decrease ) OR ( 50 ((mg decrease) OR (we decrease)) ))) OR ( 5 nm decrease ))', query time: 0.53s Refine Results
  1. 41
  2. 42
  3. 43
  4. 44

    Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects by Xiaopeng Peng (9136955)

    Published 2022
    “…The most potent compound <b>NT-6</b> exhibited high tubulin polymerization inhibitory activity (IC<sub>50</sub> = 1.5 μM) and remarkable antiproliferative potency against four cancer cell lines with an average IC<sub>50</sub> of 30 nM, better than colchicine and the hit compound <b>1f</b> (IC<sub>50</sub> of 65 and 126 nM, respectively). …”
  5. 45

    Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects by Xiaopeng Peng (9136955)

    Published 2022
    “…The most potent compound <b>NT-6</b> exhibited high tubulin polymerization inhibitory activity (IC<sub>50</sub> = 1.5 μM) and remarkable antiproliferative potency against four cancer cell lines with an average IC<sub>50</sub> of 30 nM, better than colchicine and the hit compound <b>1f</b> (IC<sub>50</sub> of 65 and 126 nM, respectively). …”
  6. 46
  7. 47
  8. 48
  9. 49
  10. 50
  11. 51
  12. 52
  13. 53
  14. 54

    Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

    Published 2021
    “…Targeting P-glycoprotein (ABCB1 or P-gp) has been recognized as a promising strategy to overcome multidrug resistance. Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo­[1,5-<i>a</i>]­pyrimidine derivative <b>WS-898</b> as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC<sub>50</sub> = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. …”
  15. 55

    Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

    Published 2021
    “…Targeting P-glycoprotein (ABCB1 or P-gp) has been recognized as a promising strategy to overcome multidrug resistance. Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo­[1,5-<i>a</i>]­pyrimidine derivative <b>WS-898</b> as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC<sub>50</sub> = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. …”
  16. 56
  17. 57
  18. 58
  19. 59
  20. 60